CPRX Q1 2022 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43M+42.7% YoY

Gross Profit

$37M86.3% margin

Operating Income

$17M40.3% margin

Net Income

$13M30.7% margin

EPS (Diluted)

$0.12

QoQ Revenue Growth

+12.5%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$247M

Total Liabilities

$27M

Stockholders' Equity

$220M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$30M	+42.7%
Gross Profit	$37M	$26M	+45.7%
Operating Income	$17M	$10M	+77.2%
Net Income	$13M	$8M	+72.8%

Revenue Segments

Product Revenue Net

$43M100%

License And Other Revenue

$56,0000%